What is the real value of metronomic chemotherapy in the treatment of gastrointestinal cancer?

References

• Bocci G, Kerbel RS. Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect nature reviews. Clin Oncol. 2016;13:659–673.
   Web of Science ®Google Scholar
• Simsek C, Esin E, Yalcin S. Metronomic chemotherapy: a systematic review of the literature and clinical experience J oncology 2019 Mar 20 2019. 2019; 1–31
   Web of Science ®Google Scholar
• García-Alfonso P, Muñoz Martín AJ, Ortega Morán L, et al. Oral drugs in the treatment of metastatic colorectal cancer. Ther Adv Med Oncol. 2021;13:17588359211009001.
   Web of Science ®Google Scholar
• Hagman H, Frödin J, Å B, et al. A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the nordic ACT2 trial. Ann Oncol. 2016 Jan;27(1):140–147.
   PubMed Web of Science ®Google Scholar
• Simkens LHJ, van Tinteren H, May A, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the dutch colorectal cancer group. Lancet. 2015;385(9980):1843–1852.
   PubMed Web of Science ®Google Scholar
• Falcone A, Cremolini C, Loupakis F, et al. FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): the phase II randomized MOMA trial. Ann Oncol. 2016 Oct;27(27):vi560.
   Google Scholar
• Huang W, Ho C, Lee C, et al. Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage III colon cancer. PloS One. 2017;12(3):e0174280.
   PubMed Web of Science ®Google Scholar
• Yutaka O, Takaho T, Yoshito A, et al. Multicenter phase II study of a new effective S-1 and irinotecan combination schedule in patients with unresectable metastatic or recurrent colorectal cancer clinical medicine insights. Oncology 2013 Dec 1;2013(7):21–30.
   Google Scholar
• Yutaka O, Teruo S, Shinjiro M, et al. Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal carcinoma. Anticancer Res. 2007 Jul 1;27(4C):2605–2611.
   PubMed Web of Science ®Google Scholar
• Allegrini G, Falcone A, Fioravanti A, et al. A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. Br J Cancer. 2008 Apr 22;98(8):1312–1319.
   PubMed Web of Science ®Google Scholar
• Shinomi I, Masaji T, Manabu K, et al. Phase 2 trial of oral S-1 combined with low-dose cisplatin for unresectable advanced pancreatic cancer. Anticancer Res. 2008 Jul 1;28(4C):2373–2377.
   PubMed Web of Science ®Google Scholar
• Isacoff WH, Reber HA, Bedford R, et al. Low-dose continuous 5-fluorouracil combined with leucovorin, nab-paclitaxel, oxaliplatin, and bevacizumab for patients with advanced pancreatic cancer: a retrospective analysis. Targ Oncol. 2018 Aug;13(4):461–468.
   PubMed Web of Science ®Google Scholar
• Roberto M, Romiti A, Onesti CE, et al. A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer. Anticancer Drugs. 2016 Feb;27(2):106–111.
   PubMed Web of Science ®Google Scholar
• He S, He S, Shen J, et al. Capecitabine “metronomic” chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy. Med Oncol. 2012 Mar;29(1):100–106.
   PubMed Web of Science ®Google Scholar
• Colleoni M, Vicario G, Graiff C, et al. Intermittent continuous infusion of fluorouracil, low-dose oral leucovorin and oral etoposide in advanced gastric cancer. Oncol Rep. 1996 Nov;3(6):1169–1172.
   PubMed Web of Science ®Google Scholar
• Brandi G, Rosa F, Agostini V, et al. Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study. Oncologist J. 2013 Nov 13,;18(12):1256–1257.
   PubMed Web of Science ®Google Scholar
• Trevisani F, Brandi G, Garuti F, et al. Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. J Cancer Res Clin Oncol. 2018 Feb;144(2):403–414.
   PubMed Web of Science ®Google Scholar
• Casadei Gardini A, Foca F, Scartozzi M, et al. Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study. Sci Rep. 2017 Feb 13;7(1):42499.
   PubMedGoogle Scholar
• Abd Elatti Khedr G, Elzawawy S, Gowil A, et al. Metronomic capecitabine versus doxorubicin in advanced hepatocellular carcinoma. Korean Clinical Oncology. 2016;12(1):32–40.
   Google Scholar
• Hsu C, Yang T, Hsu C, et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer. 2010 Feb 16;102(6):981–986.
   PubMed Web of Science ®Google Scholar
• Hsu C, Shen Y, Lin Z, et al. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol. 2010;53(1):126–131.
   PubMed Web of Science ®Google Scholar
• Shao Y, Lin Z, Hsu C, et al. Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma. Oncology. 2012 Feb;82(1):59–66.
   PubMed Web of Science ®Google Scholar
• Tajima H, Ohta T, Shinbashi H, et al. Phase I study of weekly palliative chemotherapy with low-dose third-line paclitaxel for biliary tract cancer. Mol Clin Oncol. 2017 May;6(5):753–757.
   PubMed Web of Science ®Google Scholar
• Brizzi MP, Berruti A, Ferrero A, et al. Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas A phase II trial of the piemonte oncology network. BMC Cancer. 2009 Nov 3;9(1):388.
   PubMedGoogle Scholar
• Berruti A, Fazio N, Ferrero A, et al. Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study. BMC Cancer. 2014 Mar 14;14(1):184.
   PubMed Web of Science ®Google Scholar
• Ciccolini J, Barbolosi D, Meille C et al. Pharmacokinetics and pharmacodynamics-based mathematical modeling identifies an optimal protocol for metronomic chemotherapy. Cancer Res. 2017. September;7717:4723–4733. 17. .
   PubMed Web of Science ®Google Scholar
• Geng R, Wang G, Qiu L, et al. Metronomic capecitabine as maintenance treatment after first line induction with XELOX for metastatic colorectal cancer patients. Medicine (Baltimore). 2020;99(51):e23719.
   PubMed Web of Science ®Google Scholar
• Cham K, Baker J, Chang C, et al. Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. Br J Cancer. 2010;103(1):52–60.
   PubMed Web of Science ®Google Scholar
• Perez BL, Trivedi H, Tandon M, et al. Metronomic chemotherapy for elderly patients with advanced gastric cancer: a potentially feasible alternative to therapeutic nihilism. Am J Gastroenterol. 2015;110:S504.
   Web of Science ®Google Scholar
• Chubenko V, Zagorskaya L, Lukyanchikova V, et al. Long-term survival rates in cancer patients achieved with metronomic chemotherapy (cyclophosphamide and methotrexate). J Clin Oncol. 2020;38(15_suppl):e15519.
   Web of Science ®Google Scholar
• ClinicalTrials.Gov [Internet].; cited Last accessed 10 Dec 2020]. Available from: https://www.clinicaltrials.gov/.
   Google Scholar
• Kwak G, Jo SD, Kim D, et al. Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles. J Control Release. 2017;267:203–213.
   PubMed Web of Science ®Google Scholar
• Valenzuela P, Parra K, Oaxaca D, et al. Abstract 784: pharmacodynamic biomarkers in metronomic chemotherapy: multiplex cytokine measurements in gastrointestinal cancer patients. Cancer Res. 2017;77:784.
   Web of Science ®Google Scholar